Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

This study tests a new treatment approach for newly diagnosed multiple myeloma (a cancer of plasma cells in the bone marrow) in patients who are eligible for a stem cell transplant. It combines standard transplant preparation with bispecific T-cell engagers — a new type of immunotherapy that helps the immune system identify and kill myeloma cells. **You may be eligible if...** - You have newly diagnosed multiple myeloma confirmed by standard criteria - You are eligible for high-dose therapy and stem cell transplant - You are in reasonably good health (ECOG score ≤2) - If HIV-positive: your viral load is undetectable and you are on stable HIV therapy - You are willing and able to follow the study requirements **You may NOT be eligible if...** - You have previously been treated for multiple myeloma - You are not eligible for stem cell transplant - You are pregnant or not willing to use adequate contraception - You have uncontrolled serious infections or medical conditions Talk to your doctor to see if this trial is right for you.